Immunotherapy combination shows promise in advanced bladder cancer
Combining nivolumab and ipilimumab could provide significant tumour reduction.
Bristol-Myers Squibb (BMS) has announced the publication of data showing that combining the immunotherapies nivolumab and ipilimumab could provide significant tumour reduction in patients with advanced bladder cancer. The study showed that across two different doses of the nivolumab and ipilimumab combination, 38.5% and 26.0% of adult patients with previously-treated metastatic urothelial carcinoma experienced a complete or partial reduction in their tumours. These bladder cancer data are from two cohorts of CheckMate -032, an investigational Phase I/II study and were published in the Journal for ImmunoTherapy of Cancer.
“Over the last 30 years, there has been very little improvement in survival for patients with advanced bladder cancer and the outlook for these people remains poor,” said Professor Thomas Powles, Clinical Professor of Genitourinary Oncology, Barts Cancer Institute. “We have already seen that this combination of nivolumab plus ipilimumab can work effectively in other cancers such as advanced melanoma and these results provide an early indication of how this combination could transform how we treat bladder cancer in the future.”
Nivolumab has an innovative mode of action that works by harnessing the ability of the immune system to fight cancer. Ipilimumab has a similar mode of action but acts on a different checkpoint, called CTLA-4. Combining the two medicines aims to block both receptors at the same time, which then potentially allows the immune system to recognise and destroy tumour cells.
In the clinical trial, the incidence of Grade 3-4 treatment-related adverse events (AEs) was 30.8% in the nivolumab 1 mg/kg plus ipilimumab 3 mg/kg cohort; treatment-related AEs led to discontinuation of therapy in 7.7% of patients.
“At BMS, we have made significant strides to further the scientific understanding of immunotherapy combinations for treating a range of tumour types. These latest data indicate the future potential of this innovative approach for patients who are in the advanced stages of bladder cancer,” said Sue Bailey, Disease Area Head, Oncology, BMS, UK and Ireland. “Our goal is to change survival expectations in cancer and we hope that in the future, these data translate into improved expectations for patients with this disease.”
The combination of nivolumab plus ipilimumab in bladder cancer is investigational and not licensed for use. This combination therapy is licensed and available on the NHS for the treatment of advanced melanoma
.Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance